Hong Kong Stocks Movement | Biotech Concept Stocks Lead Declines as BD Deals Cool and Rate Cut Expectations Fade

Stock News11-21

Biotech concept stocks led declines in Hong Kong. As of press time, HBM HOLDINGS-B (02142) fell 9.15% to HK$12.81, BRII-B (02137) dropped 7.56% to HK$1.59, REMEGEN (09995) declined 5.83% to HK$80, and INNOVENT BIO (01801) slid 6.18% to HK$86.5.

Market sources indicate signs of cooling in biotech business development (BD) deals. Data from PharmaCube shows China-related transactions totaled $60.8 billion in the first half of 2025, up 129% year-on-year. However, growth slowed to 64% YoY in the first three quarters of 2025, with total deal value reaching $93.7 billion, suggesting a deceleration in domestic biotech BD activity starting Q3.

Additionally, the resilient U.S. September jobs report prompted Morgan Stanley to withdraw its forecast for a 25-basis-point Fed rate cut in December. The bank now expects rate reductions in January, April, and June 2026, lowering the target range to 3%-3.25%. Analysts note that fading Fed rate cut expectations may pressure biotech valuations and overseas life sciences investment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120147062?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-21 11:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120147062","market":"sh","top_or_hot":-1,"title":"Hong Kong Stocks Movement | Biotech Concept Stocks Lead Declines as BD Deals Cool and Rate Cut Expectations Fade","media":"Stock News","content":"<p>Biotech concept stocks led declines in Hong Kong. As of press time, HBM HOLDINGS-B (02142) fell 9.15% to HK$12.81, BRII-B (02137) dropped 7.56% to HK$1.59, REMEGEN (09995) declined 5.83% to HK$80, and INNOVENT BIO (01801) slid 6.18% to HK$86.5.</p>\n<p>Market sources indicate signs of cooling in biotech business development (BD) deals. Data from PharmaCube shows China-related transactions totaled $60.8 billion in the first half of 2025, up 129% year-on-year. However, growth slowed to 64% YoY in the first three quarters of 2025, with total deal value reaching $93.7 billion, suggesting a deceleration in domestic biotech BD activity starting Q3.</p>\n<p>Additionally, the resilient U.S. September jobs report prompted Morgan Stanley to withdraw its forecast for a 25-basis-point Fed rate cut in December. The bank now expects rate reductions in January, April, and June 2026, lowering the target range to 3%-3.25%. Analysts note that fading Fed rate cut expectations may pressure biotech valuations and overseas life sciences investment.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stocks Movement | Biotech Concept Stocks Lead Declines as BD Deals Cool and Rate Cut Expectations Fade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stocks Movement | Biotech Concept Stocks Lead Declines as BD Deals Cool and Rate Cut Expectations Fade\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-21 11:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biotech concept stocks led declines in Hong Kong. As of press time, HBM HOLDINGS-B (02142) fell 9.15% to HK$12.81, BRII-B (02137) dropped 7.56% to HK$1.59, REMEGEN (09995) declined 5.83% to HK$80, and INNOVENT BIO (01801) slid 6.18% to HK$86.5.</p>\n<p>Market sources indicate signs of cooling in biotech business development (BD) deals. Data from PharmaCube shows China-related transactions totaled $60.8 billion in the first half of 2025, up 129% year-on-year. However, growth slowed to 64% YoY in the first three quarters of 2025, with total deal value reaching $93.7 billion, suggesting a deceleration in domestic biotech BD activity starting Q3.</p>\n<p>Additionally, the resilient U.S. September jobs report prompted Morgan Stanley to withdraw its forecast for a 25-basis-point Fed rate cut in December. The bank now expects rate reductions in January, April, and June 2026, lowering the target range to 3%-3.25%. Analysts note that fading Fed rate cut expectations may pressure biotech valuations and overseas life sciences investment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02137","symbol_name":"腾盛博药-B","start_time":0,"source_url":"","article_id":"1120147062","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120147062","pubTimestamp":1763694027,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Biotech concept stocks led declines in Hong Kong. As of press time, HBM HOLDINGS-B (02142) fell 9.15% to HK$12.81, BRII-B (02137) dropped 7.56% to HK$1.59, REMEGEN (09995) declined 5.83% to HK$80,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","02137":"腾盛博药-B","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","BK1161":"生物科技","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","06978":"永泰生物-B","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","BK1587":"次新股","02142":"和铂医药-B","BK1574":"生物医药B类股","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","09995":"荣昌生物","BK1583":"高瓴概念","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","01801":"信达生物","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","BK1589":"北水核心资产","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC"},"translate_title":"港股动向|BD交易降温降息预期消退，生物科技概念股领跌","themeId":"594b3e71116532d11de7e9d6ad4f64f1","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"06978":1,"02142":1,"09995":1,"02137":1,"01801":1},"content_text":"Biotech concept stocks led declines in Hong Kong. As of press time, HBM HOLDINGS-B (02142) fell 9.15% to HK$12.81, BRII-B (02137) dropped 7.56% to HK$1.59, REMEGEN (09995) declined 5.83% to HK$80, and INNOVENT BIO (01801) slid 6.18% to HK$86.5.\nMarket sources indicate signs of cooling in biotech business development (BD) deals. Data from PharmaCube shows China-related transactions totaled $60.8 billion in the first half of 2025, up 129% year-on-year. However, growth slowed to 64% YoY in the first three quarters of 2025, with total deal value reaching $93.7 billion, suggesting a deceleration in domestic biotech BD activity starting Q3.\nAdditionally, the resilient U.S. September jobs report prompted Morgan Stanley to withdraw its forecast for a 25-basis-point Fed rate cut in December. The bank now expects rate reductions in January, April, and June 2026, lowering the target range to 3%-3.25%. Analysts note that fading Fed rate cut expectations may pressure biotech valuations and overseas life sciences investment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120147062","isCrawlerRequest":true}